Over 35 CMOs / CDMOs in China claim to offer a variety of services related to development, By Roots Analysis

Owing to benefits, such as reduced manufacturing costs, availability of cheap and skilled labor, and a supportive regulatory landscape, biopharmaceutical developers from across the globe, are increasingly outsourcing their manufacturing operations to China based CMOs. Further, in order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives. 

• A detailed review of the overall landscape of companies offering contract manufacturing services for biopharmaceuticals in China, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities, as well as location of these facilities, type of business segment, type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, stability studies, quality assurance and control, scale-up, downstream processing, regulatory support, data analytics and reporting, and others), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression system(s) used (mammalian, microbial and others), type of bioreactor(s) used (single-use bioreactors and stainless steel bioreactors) and its mode of operation (batch, fed-batch and perfusion), type of packaging, and affiliations to regulatory accreditations and certifications (if any). 
• An analysis of the various partnerships pertaining to biopharmaceutical manufacturing in China, which have been established since 2016, based on several parameters, such as the year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area of the deal, target indication, most active players (in terms of number of partnerships signed), and geography.
• An analysis of the various expansion initiatives undertaken by contract manufacturers in China, in order to augment their capabilities, over the period 2016-2020 (till February), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.

 

 

To order this 250+ page report, which features 100+ figures and 120+ tables, please visit this link

 

The USD 2.6 billion (by 2030) financial opportunity within the China biopharmaceutical contract manufacturing market has been analyzed across the following segments:

• Type of Product
• API
• FDF

 

• Type of Expression System Used
• Mammalian
• Microbial
• Others

 

• Scale of Operation
• Preclinical / Clinical
• Commercial

 

• Size of Manufacturer
• Small
• Mid-sized
• Large / Very Large

 

• Type of Biologic
• Antibody
• Vaccine
• Others

 

The China Biopharmaceutical Contract Manufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• ChemPartner Biologics
• JHL Biotech
• JOINN Biologics
• MabPlex
• Mycenax Biotech
• WuXi AppTec

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Case Study: Comparison of Small Molecules and Large Molecules
 

5. Competitive Landscape
 

6. Company Profiles
 

7. Partnerships
 

8. Recent Expansions
 

9. Clinical Trial Analysis
 

10. Regional Capability Analysis
 

11. Capacity Analysis
 

12. Big Pharma Biopharmaceutical Manufacturing Initiatives in China
 

13. Make Versus Buy Decision Making Framework
 

14. Market Sizing and Opportunity Analysis

 

15. COVID-19 Impact on China Biopharmaceutical CMO Market

 

16. SWOT Analysis

 

17. Future of the China Biopharmaceutical CMO Market

 

18. Interview Transcripts

 

19. APPENDIX 1: TABULATED DATA

 

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]